Chemed’s earnings beat puts fresh attention on the stock

Chemed (CHE) is back on investors’ radar after its latest quarterly report, where revenue of $657.5 million and an earnings beat exceeded analysts’ expectations and coincided with the stock moving higher.

Chemed’s recent earnings beat has coincided with a strong 90 day share price return of 22.94%. However, the 1 year total shareholder return is still down 18.04%, so recent momentum contrasts with a weaker longer term picture.

If this earnings driven move has you reassessing opportunities in healthcare, it can be useful to see what else is moving and compare Chemed with 39 healthcare AI stocks

With Chemed trading at $453.15, close to analysts’ $446.50 price target yet showing an intrinsic discount estimate of 33.63%, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 1.5% Overvalued

Chemed’s most followed narrative pegs fair value at $446.50 using a 7.11% discount rate, slightly below the latest close at $453.15. This frames a tight valuation gap.

The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (for example, Pinellas and Marion) is expected to materially expand VITAS's service footprint. This aligns with the continued aging U.S. population and the shift toward home-based care, both cited as key drivers of higher patient volumes and long-term top-line revenue growth.

This raises the question of what earnings path and margin profile would need to hold for Chemed to justify that fair value, and how buybacks may affect the share count.

Result: Fair Value of $446.50 (OVERVALUED)

However, Chemed’s story also carries real pressure points, including reimbursement caps at VITAS, as well as weaker residential demand and higher insurance and labor costs at Roto-Rooter.

Another View: Chemed’s valuation through the fair P/E lens

The DCF based narrative sees Chemed as about 1.5% overvalued around $446.50 per share, yet on P/E the picture looks different. Chemed trades at 23.1x earnings, close to its fair ratio of 23.2x and far below the 104.4x peer average. This points to limited multiple risk but also a tighter margin of safety. Which signal do you weigh more heavily?

For investors who prefer simple ratios over cash flow models, this P/E view offers a straightforward cross check on the story. The fair ratio also gives a sense of where the market could gravitate if sentiment normalizes. It still leaves the question of how comfortable you are with paying close to that implied benchmark for Chemed’s earnings power. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Chemed’s mixed signals on valuation and recent price action, how does the balance of concern and optimism sit with you right now? Take a moment to weigh both sides of the story, then use the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Chemed?

If Chemed has sharpened your focus, do not stop here; widen your opportunity set with a few targeted stock ideas built from clear, data driven filters.

• Target stability first by checking companies screened for resilience in tougher conditions through the 67 resilient stocks with low risk scores
• Hunt for potential bargains by scanning quality businesses with room for upside using the 43 high quality undervalued stocks
• Spot resilient earners with healthy financial foundations by reviewing the solid balance sheet and fundamentals stocks screener (48 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.